ABILITY Neurotech, a Swiss brain-computer interface company spun out of the Wyss Center for Bio and Neuroengineering in Geneva in March 2025, has completed a first-in-human intraoperative trial of its fully implantable BCI at TUM University Hospital Rechts der Isar in Munich. Up to five patients undergoing brain tumour surgery had 20 to 30 minutes of intraoperative neural signal recording with the device. A chronic implant trial in ALS patients at UMC Utrecht in the Netherlands and TU Graz in Austria is scheduled for Q4 2026, with medical device approval already granted by NedMec, the Dutch medical research ethics committee, in May 2026.
What the device is
Public coverage has framed ABILITY’s device as an infrared or optical BCI. The framing is misleading. ABILITY’s device is an electrocorticography (ECoG) surface-electrode implant that sits on the cortical surface under a closed scalp and is implanted sub-scalp. The neural sensing is electrical, in the same category as Precision Neuroscience’s surface array and distinct from intracortical probes such as Neuralink, Paradromics or Blackrock, and distinct from endovascular systems such as Synchron.
The “optical” part of ABILITY’s design is the wireless data transmission link. The implant is battery-free and paired inductively with an externally worn headpiece. Raw high-bandwidth neural data is transmitted through intact scalp skin to the wearable using a proprietary laser-based transcutaneous optical link. That optical channel is how the system sidesteps the bandwidth ceilings that constrain Bluetooth and standard radio-frequency implants. It does not read the brain optically.
The device is electrode-agnostic. The first clinical configuration uses a 128-channel high-density ECoG array sampled at 30,000 samples per second per channel, per CEO Rotem Kopel to IEEE Spectrum on 20 August 2026.
The Munich intraoperative trial
TUM University Hospital Rechts der Isar’s Department of Neurosurgery ran the intraoperative first-in-human. Enrolment was up to five patients already undergoing brain tumour surgery, with 20 to 30 minutes of neural signal recording added during the operation. The purpose was real-world validation of the signal acquisition chain in humans, not a therapeutic endpoint. There are no patient outcome claims to report from this trial and the company has not made any.
The Q4 chronic ALS trial
The chronic implant trial has NedMec approval as of May 2026 and is scheduled to start in Q4 2026. Sites are UMC Utrecht (Netherlands) and TU Graz (Austria), running under the INTRECOM consortium for home-use communication and speech restoration in ALS patients. The Q4 trial moves the device from intraoperative signal acquisition to sustained implantation in the target patient population.
Scientific lineage
ABILITY’s scientific lineage traces to Professor John Donoghue, a founding director of the Wyss Center in Geneva and a pioneer of the BrainGate consortium in the United States. Wyss Center’s internal BCI programme ran for roughly a decade before ABILITY spun out in March 2025. CEO is Rotem Kopel.
Where ABILITY sits in the commercial BCI cohort
ABILITY sits in the epicortical surface-electrode category alongside Precision Neuroscience globally and Weiling Medical in China (whose RMB 100 million-plus funding round InsideBCI covered on 17 August 2026). The differentiation is the transcutaneous optical data link and the battery-free inductive powering, which together move the implant closer to a fully sealed, no-percutaneous-connector architecture. Intracortical operators (Neuralink, Paradromics, Blackrock, Motif, StairMed WRS02) sit in a different category with different signal fidelity and different surgical risk. Endovascular operators (Synchron, Nankai University’s Duan Feng team, Xuanwu Hospital’s Duan Wanru team) sit in a third category. Non-invasive optical operators such as Kernel and Openwater, and DARPA’s Firefox programme announced on 17 August 2026, are optical at the sensing layer and are not comparable to ABILITY on modality.
The Q4 Utrecht-Graz chronic trial will be the first read on ABILITY’s clinical performance in target patients.
Regulatory posture
ABILITY’s public regulatory footprint is European: NedMec approval for the Utrecht chronic trial, TUM’s German ethics review for the Munich intraoperative trial. No US FDA Investigational Device Exemption, De Novo, 510(k), or Breakthrough Device Designation has been publicly reported.
What to watch
The Q4 2026 UMC Utrecht and TU Graz chronic implant readouts. Safety profile at 30, 90 and 180 days, along with the first sustained ALS communication output from an implanted patient, will define whether ABILITY’s transcutaneous optical data link and battery-free architecture perform in a real target patient over time.
Whether ABILITY files for a US FDA regulatory pathway following successful European chronic data. The European regulatory posture is a viable commercial route in Europe, but US market access requires FDA and the company’s timing on that filing is a signal of commercial ambition.
Whether a peer-reviewed publication accompanies the Q4 chronic implant. Precision Neuroscience and StairMed have both published on their surface and intracortical systems respectively. ABILITY’s Nature Communications paper by the Wyss Center team on locked-in ALS communication predates the spinout; a first ABILITY-branded publication would establish the commercial company’s scientific footprint distinct from the Wyss Center parent.